Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1181-1200 of 2,120 trials

Multiple Myeloma: SABLe Study with Selinexor

We are investigating a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The study aims to evaluate how well the treatment works and its effects on quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Triple Negative Breast Cancer: Sacituzumab Govitecan and Pembrolizumab Study

We are testing a new treatment combination for patients with triple negative breast cancer who have residual disease after surgery. The study aims to see if this combination improves survival compared to standard treatment options.

Triple Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Advanced Lung Cancer: Amivantamab and Lazertinib Study

We are exploring a new treatment combination for people with advanced non-small cell lung cancer who have an EGFR mutation and have not responded to earlier therapies. The goal is to see if this combination can improve treatment outcomes and safety.

Advanced Non-Small Cell Lung Cancer (NSCLC)1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

Chronic Low Back Pain: Tricortin 1000 Study

We are testing Tricortin 1000 to see if it helps relieve pain better than a placebo and an existing treatment for chronic low back pain. This study aims to improve pain management for those experiencing acute flare-ups.

Low Back Pain≤3 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Major Depressive Disorder: Liposom Forte with Citalopram

We are studying whether Liposom Forte can enhance and speed up the response to citalopram in elderly patients with Major Depressive Disorder. The trial also looks at the safety of this treatment.

Major Depression3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesPsychiatry

Head and Neck Cancer: Carboplatin, Paclitaxel, and Cetuximab Study

We are studying a combination of three medications for patients with recurrent or metastatic head and neck squamous cell carcinoma who did not respond to previous treatments. The goal is to see if this combination improves response rates and overall survival.

Head and Neck Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Elderly Primary CNS Lymphoma: High-Dose Chemotherapy Study

We are comparing a high-dose chemotherapy followed by stem cell transplantation to standard chemotherapy for elderly patients with primary CNS lymphoma. The goal is to see which treatment leads to better survival and quality of life.

Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Viral Infections After Stem Cell Transplant: Multispecific T-Cell Therapy

We are studying a new treatment using multispecific T-cells for patients with viral infections that resist chemotherapy after stem cell transplantation. The goal is to see if this therapy can improve symptoms and overall health.

Viral Infections After Stem Cell Transplant>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesHematologyInfectious DiseasesOncology

Amantadine for Improving Alertness in ICU Patients

We are studying whether Amantadine can enhance responsiveness in patients receiving intensive care. The trial will measure changes in alertness over several days using established clinical scoring systems.

Unresponsive Wakefulness Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Prostate Cancer: New Radioactive Treatment Study

We are testing a new radioactive drug for adults with metastatic castration-resistant prostate cancer who have not had chemotherapy. The study will assess the safety and how well the treatment works in these patients.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Standard MedicinesOncology

Solid Tumors: MCLA-128 Treatment Study

We are studying a new bispecific antibody, MCLA-128, in patients with solid tumors that have an NRG1 fusion. The goal is to evaluate its safety and how well it may work against these tumors.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Chemotherapy and Immunotherapy for Pancoast Tumor in Lung Cancer

We are studying the effects of chemotherapy and immunotherapy before and after surgery in patients with non-small cell lung cancer located in the upper part of the lungs. The goal is to see if this approach improves survival and treatment outcomes.

Pancoast's TumorEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Breast Cancer: Trastuzumab Deruxtecan vs. CDK4/6 Inhibitors

We are studying whether trastuzumab deruxtecan is more effective than a combination of CDK4/6 inhibitors and endocrine therapy for patients with HR-positive, HER2-low advanced breast cancer. This research aims to improve treatment options for this specific group of patients.

Locally Recurrent or Metastatic Hormone Receptor-Positive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyOncology

Small-Cell Lung Cancer: Durvalumab and Olaparib Maintenance Therapy

We are studying the effects of a combination of durvalumab and olaparib for patients with HRD-positive extensive disease small-cell lung cancer after initial treatment. The goal is to see if this maintenance therapy improves outcomes and is safe for patients.

Extensive Stage Small Cell Lung Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Duchenne Muscular Dystrophy: Satralizumab Study

We are studying the effects of satralizumab in children and teens with Duchenne muscular dystrophy. This trial aims to see if it is safe and how it impacts bone health and metabolism.

Duchenne Muscular Dystrophy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyNeurologyPediatrics

Anesthesia in Young Children: Low-Dose vs. Standard Sevoflurane

We are comparing the effects of low-dose sevoflurane combined with dexmedetomidine and remifentanil against standard sevoflurane anesthesia on cognitive development in children under 2 years old. The goal is to see which method supports better brain development as they grow.

General Anesthesia in Young Children>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Cardiac Surgery: Fibrinogen Concentrate Study

We are testing a new treatment to manage bleeding in patients undergoing complex cardiac surgery. The goal is to see if it reduces the need for blood transfusions compared to a placebo.

Functional Disturbances After Cardiac SurgeryBleeding in Cardiac Surgery Patients>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Hemolytic Uremic Syndrome: INM004 Treatment for Kids

We are studying a new treatment for children with Hemolytic Uremic Syndrome caused by E. coli to see if it helps improve kidney function and reduce complications. The trial will also evaluate the safety of this treatment.

Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesNephrologyPediatrics

Advanced Cancer: JK06 Antibody Drug

We are testing a new drug called JK06 for patients with advanced cancer that cannot be removed by surgery. The study aims to evaluate its safety and how well it may work in treating this type of cancer.

Unresectable, Locally Advanced or Metastatic CancerSafety phase (I)Efficacy phase (II)No PlaceboOncology

Soft Tissue Sarcomas: INT230-6 Treatment Study

We are investigating a new treatment for adults with advanced soft tissue sarcomas to see if it works better than standard care. The study will also look at side effects and quality of life for participants.

Myxoid LiposarcomaDedifferentiated LiposarcomaRound Cell Liposarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology